amivantamab Rybrevant
Selected indexed studies
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. (Ann Oncol, 2024) [PMID:37879444]
- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. (N Engl J Med, 2024) [PMID:38924756]
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. (N Engl J Med, 2023) [PMID:37870976]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. (2024) pubmed
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. (2023) pubmed
- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. (2024) pubmed
- Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. (2024) pubmed
- Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. (2025) pubmed
- MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. (2022) pubmed
- Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. (2024) pubmed
- PMID:37643266 (2023) pubmed
- Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report. (2025) pubmed
- Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. (2021) pubmed